Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Tight liquidity NBB
Cash and receivables cover 6 % of short-term debt in 2025; threshold 65 %.
Financials
Financial year 2025
ASTERION RESEARCH & DEVELOPMENT from Gent, company number BE0682704608, closed financial year 2025 with a result of € -621,245 after tax. For that financial year ASTERION RESEARCH & DEVELOPMENT recorded a gross margin of € -91,977 and equity of € 1.6 million. Compared with financial year 2024, the result moved from € 37,163 to € -621,245. The company made a loss. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 24, 2026.
€ 1.6 million
▲ € 1.7 million vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -621,245
▼ still € 37,163 profit in 2024
Profit after tax over the fiscal year.
€ 0
▼ 100% vs 2024
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -655,956.
People and assets in 2025
€ 4,907
▼ 24% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 397,492
▲ 20% vs 2024
Loans from banks and other lenders, long and short.
€ 58,650
▲ 78% vs 2024
Supplier invoices still open on the last day of the fiscal year.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 206,396 | € 94,418 | € 119,958 | € -91,977 | ▼ € 211,936 |
| Profit after taxes | € 249,794 | € 83,655 | € 37,163 | € -621,245 | ▼ € 658,407 |
| Equity | € -136,978 | € -53,323 | € -16,161 | € 1,644,281 | ▲ € 1.7 million |
| Total debts | € 790,850 | € 492,378 | € 587,586 | € 662,480 | ▲ 13% |
| Cash | € 1 | € 5,990 | € 39 | € 0 | ▼ 100% |
| Retained profit | € -155,528 | € -71,873 | € -34,711 | € -655,956 | ▼ € 621,245 |
| Bank debt | € 506,241 | € 162,751 | € 330,894 | € 397,492 | ▲ 20% |
| Balance sheet total | € 653,872 | € 439,054 | € 571,425 | € 2,306,761 | ▲ € 1.7 million |
By gross margin, ASTERION RESEARCH & DEVELOPMENT ranks 10th of 10 companies with main activity “Speur- en ontwikkelingswerk op biotechnologisch gebied” in Gent that publish figures (fiscal year 2025).
Key figures of ASTERION RESEARCH & DEVELOPMENT, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
Ask about ASTERION RESEARCH & DEVELOPMENT the way you would ask their accountant.
Answers from the filed annual accounts, the Belgian Official Gazette and the CBE register.
Connect ChatGPT or Claude for free- ChatGPT
- Claude
Free account, no payment card. Key figures unlimited, the annual accounts and deeds of 10 companies a month. Need more? Get in touch, we are looking for our first pilot users.
What happened to ASTERION RESEARCH & DEVELOPMENT?
What happened at ASTERION RESEARCH & DEVELOPMENT in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: loss of € 621,245 (▼ € 658,407 vs 2024). Source: NBB ↗
- New establishment in Gent. KBO
- Jeroen Hofenk became a director. NBB
- Start of the company according to the CBE. KBO
In short
From € 249,794 profit in 2022 to € 621,245 loss in 2025.
Best year ever: 2022, with € 249,794 profit.
Management
The stake of Marcelis Management Services comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
ASTERION RESEARCH & DEVELOPMENTBehind ASTERION RESEARCH & DEVELOPMENT is Jeroen Hofenk. The shares are held by Marcelis Management Services (28.8%). It owns 52.8% of Swiftpharma and 30% of Bombi Biomics itself.
Directors
According to the 2025 annual accounts
since 2017
Shareholders
Participations
52.8%
Bombi Biomics
30%
Establishments
Establishment units
Physical locations of this company
Karel van de Woestijnestraat 6
9000 Gent
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 2 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Similar companies in Gent
Same main activity (Speur- en ontwikkelingswerk op biotechnologisch gebied), 13 active companies in Gent, largest first.
€ 2 million gross margin · 2025
€ 602,932 gross margin · 2025
€ 116,857 gross margin · 2025
€ 98,498 gross margin · 2025
€ 84,912 gross margin · 2024
€ 31,462 gross margin · 2025
Details
- Company number
- 0682.704.608
- VAT number
- BE 0682.704.608
- Registered office
- Karel van de Woestijnestraat 6, 9000 Gent
- Names & denominations
- ASTERION RESEARCH & DEVELOPMENT
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 9 October 2017
- Peppol
- Active · Active since 20 May 2025
- Activities · NACE
Speur- en ontwikkelingswerk op biotechnologisch gebied
Vervaardiging van farmaceutische grondstoffen